GlassScriptPhysician profile
Sheridan Lam
NPI 1689673964
$2,267.49
in general payments reported to CMS, 2019-2025
20 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $118 · 2021: $291 · 2022: $395 · 2023: $330 · 2024: $377 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $368.26 | 2020-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Bausch & Lomb Americas INC. | $270.94 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $269.20 | 2019-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $201.26 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $134.96 | 2020-2022 | |
| Rxsight INC | $121.03 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $105.92 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $105.84 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $104.66 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $103.39 | 2019-2023 | |
| Dompe US, INC. | $93.27 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $77.05 | 2022-2025 | Iyuzeh |
| Harrow Eye, LLC | $72.28 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $64.36 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $41.13 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $34.06 | 2019-2024 | Idose |
| Biotissue Holdings INC. | $29.42 | 2020-2021 | |
| Shire North American Group INC | $29.22 | 2019 | |
| Optos, INC. | $24.23 | 2019 | |
| Ocular Therapeutix, INC. | $17.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheridan Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.